

# JD-5037

**Catalog No: tcsc6325**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

1392116-14-1

**Formula:**

$C_{27}H_{27}Cl_2N_5O_3S$

**Pathway:**

GPCR/G Protein

**Target:**

Cannabinoid Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**


572.51

## Product Description

JD-5037 is a novel, peripherally restricted **CB<sub>1</sub>R** antagonist with an **IC<sub>50</sub>** of 1.5 nM.

IC50 & Target: IC50: 1.5 nM (CB<sub>1</sub>R)<sup>[1]</sup>

**In Vivo:** JD5037 (3 mg/kg/d, i.p.) induces equal reductions in body weight, attenuates the HFD-induced hyperglycemia, and reduces the HFD-induced hepatic injury and steatosis in obese Magel2-null mice<sup>[2]</sup>. JD5037 (3 mg/kg/day, p.o.) significantly reduces the size of tumors and abrogates the tumor in DEN-treated mice. JD5037 attenuates the AEA levels in HCC samples from mice<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!